17,261 trials
Alopecia Areata
Primary: Change in Alopecia Areata Half Head Severity Score (AAHHSS) at 12 Weeks Compared to Baseline — -17.75 score on a scale
Non Small Cell Lung Cancer
Primary: Percentage of Participants With Progression Free Survival — 64 percentage of participants
Smallpox
Primary: Geometric Mean Titer (GMT) Based on Vaccinia-specific Individual Peak Plaque Reduction Neutralization Titers (PRNT) Following 2 Doses of IMVAMUNE® Lyophilized Versus…
Postoperative Pain
Primary: Total Use of Opioid Rescue Analgesia — 53.65; 66.56; 53.73 mg morphine equivalents
Diabetes Mellitus, Insulin-Dependent
Primary: Area Under the Curve (AUC)(0-2 h) of C-peptide Response to the Mixed Meal Tolerance Test (MMTT) at Week 13 — 4.026; 3.886 log(ng*hr/ml [0-2 h]+1) — p=0.3303
Endometrial Cancer · Papillary Serous · Clear Cell Endometrial Cancer
Primary: Number of Patients Completing the Protocol — 27 Participants
Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Myelodysplastic Syndrome
Primary: Incidence of Acute Graft Versus Host Disease (GVHD) Grade III/IV — 2; 2 participants
Autism · Autism Spectrum Disorder
Primary: Resting State Functional Connectivity (rsFC) Salience Network (Anterior Cingulate Cortex (ACC) and Insula Versus Visual Cortex) — 0.338; 0.400; 0.428; 0.522 z-scores…
Thyroid Cancer
Primary: Objective Response Rate (ORR) as of Week 24 (ORR24wk) — 57.3; 40.3 percentage of participants
Postoperative Pain · Inguinal Hernia
Primary: Total Use of Opioid Rescue Analgesia Over 0 to 24 Hours — 18.48; 24.60 mg
KRAS NP_004976.2:p.G12R · Stage III Pancreatic Cancer AJCC v6 and v7 · Stage IV Pancreatic Cancer AJCC v6 and v7
Primary: Proportion of Participants With an Objective Response (Partial Response + Complete Response) — 0; 0; 0; 0 Proportion of participants
Metastatic Breast Cancer
Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI…
Blepharitis
Primary: Change From Baseline in Ocular Discomfort — -4.1; -2.4 score on a scale
Basal Cell Nevus Syndrome · Gorlin Syndrome
Primary: Number of New Surgically Eligible Basal-cell Carcinomas — 34; 2 events per patient year
Mucositis
Primary: Change in Pain Scores — 2 score on a scale